Piramal Pharma Achieves 1,500th ADC Batch Milestone, Reinforcing Leadership in Oncology Manufacturing
- Piramal Pharma Solutions completed its 1,500th antibody-drug conjugate batch, reinforcing its leadership in ADC manufacturing.
- The Grangemouth facility supports Piramal's ADCelerate™ program, improving the transition from R&D to large-scale production.
- Piramal's expertise ensures high-quality manufacturing standards for bioconjugates, reaffirming its commitment to delivering innovative therapies.
Piramal Pharma Achieves Milestone in Antibody-Drug Conjugate Manufacturing
Piramal Pharma Solutions has attained a significant milestone with the completion of its 1,500th antibody-drug conjugate (ADC) batch at its Grangemouth facility in the UK. This achievement, announced on March 16, 2026, underscores Piramal's position as a leading Contract Development and Manufacturing Organization (CDMO) specializing in bioconjugate therapies for oncology patients. With over two decades of experience and being the first FDA-approved ADC CDMO, Piramal sets a benchmark in the ADC landscape, showcasing its ability to produce biotherapeutics that are essential for improving patient outcomes.
The Grangemouth facility plays a critical role in Piramal's ADCelerate™ program, which streamlines the transition from R&D to Good Manufacturing Practice (GMP) production. This program facilitates efficient technology transfers backed by robust project management and quality assurance teams. By leveraging integrated solutions that encompass everything from proof-of-concept studies to large-scale commercial production, Piramal maintains its commitment to delivering innovative therapies. The facility's recent accomplishment of producing 1,500 ADC batches—including clinical, commercial, and non-GMP products—illustrates its capacity to handle diverse manufacturing needs backed by a solid regulatory record.
Piramal's extensive portfolio of produced bioconjugates represents a combination of experience and pioneering technology that has positioned the company as a leader in the market. The expertise of the Science Collective enhances project outcomes through strategic guidance and technical insight, securing high-quality manufacturing practices that comply with industry standards. With this recent milestone, Piramal reaffirms its dedication to delivering impactful biotherapeutics, ensuring that patients have access to the vital therapies they need.
In other relevant industry developments, Whitehawk Therapeutics, a clinical-stage oncology therapeutics company, announces its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting from April 17-22, 2026. The company intends to present three preclinical abstracts on its next-generation ADC portfolio, which focuses on optimized designs aimed at improving cancer patient outcomes, featuring promising therapeutic indices.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

